CA3241845A1 - Compounds - Google Patents
CompoundsInfo
- Publication number
- CA3241845A1 CA3241845A1 CA3241845A CA3241845A CA3241845A1 CA 3241845 A1 CA3241845 A1 CA 3241845A1 CA 3241845 A CA3241845 A CA 3241845A CA 3241845 A CA3241845 A CA 3241845A CA 3241845 A1 CA3241845 A1 CA 3241845A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- synthesis
- treatment
- present disclosure
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904268 | 2021-12-24 | ||
| AU2021904268A AU2021904268A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051591 WO2023115165A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241845A1 true CA3241845A1 (en) | 2023-06-29 |
Family
ID=86900872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241845A Pending CA3241845A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163044A1 (enExample) |
| EP (1) | EP4452979A4 (enExample) |
| JP (1) | JP2025501141A (enExample) |
| KR (1) | KR20240128059A (enExample) |
| CN (1) | CN118974044A (enExample) |
| AU (1) | AU2022422215A1 (enExample) |
| CA (1) | CA3241845A1 (enExample) |
| IL (1) | IL313857A (enExample) |
| MX (1) | MX2024007911A (enExample) |
| WO (1) | WO2023115165A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| TW202425965A (zh) | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| EP4735441A1 (en) | 2023-06-28 | 2026-05-06 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| JP2026524104A (ja) * | 2023-06-28 | 2026-07-17 | サイロ プロプリエタリー リミテッド | 化合物 |
| WO2026030052A1 (en) | 2024-07-31 | 2026-02-05 | Fmc Corporation | Fungicidal substituted azoles |
| WO2026137050A1 (en) * | 2024-12-24 | 2026-07-02 | Psylo Pty Ltd | Compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5977131A (en) * | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| GB9819020D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| EP1513521A2 (en) * | 2002-05-30 | 2005-03-16 | Alcon, Inc. | Pyranoindazoles and their use for the treatment of glaucoma |
| US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| ES2374581T3 (es) | 2006-07-06 | 2012-02-20 | Abbott Healthcare Products B.V. | Derivados de azaindol con una combinación de agonismo parcial del receptor nicotínico de la acetilcolina e inhibición de la reabsorción de dopamina. |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| PL2485731T4 (pl) * | 2009-10-06 | 2017-07-31 | Millennium Pharmaceuticals, Inc. | Związki heterocykliczne użyteczne jako inhibitory PDK1 |
| US9073851B2 (en) * | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
| WO2017125351A1 (en) | 2016-01-21 | 2017-07-27 | Laboratorios Lesvi Sl | Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole |
| CA3182093A1 (en) * | 2020-06-10 | 2021-12-16 | Florence Wagner | Tricyclic psychoplastogens and uses thereof |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
-
2022
- 2022-12-23 JP JP2024538669A patent/JP2025501141A/ja active Pending
- 2022-12-23 KR KR1020247024904A patent/KR20240128059A/ko active Pending
- 2022-12-23 CA CA3241845A patent/CA3241845A1/en active Pending
- 2022-12-23 CN CN202280091203.9A patent/CN118974044A/zh active Pending
- 2022-12-23 AU AU2022422215A patent/AU2022422215A1/en active Pending
- 2022-12-23 MX MX2024007911A patent/MX2024007911A/es unknown
- 2022-12-23 WO PCT/AU2022/051591 patent/WO2023115165A1/en not_active Ceased
- 2022-12-23 EP EP22908927.1A patent/EP4452979A4/en active Pending
- 2022-12-23 IL IL313857A patent/IL313857A/en unknown
- 2022-12-23 US US18/722,007 patent/US20250163044A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022422215A1 (en) | 2024-08-01 |
| JP2025501141A (ja) | 2025-01-17 |
| WO2023115165A1 (en) | 2023-06-29 |
| KR20240128059A (ko) | 2024-08-23 |
| US20250163044A1 (en) | 2025-05-22 |
| CN118974044A (zh) | 2024-11-15 |
| EP4452979A1 (en) | 2024-10-30 |
| MX2024007911A (es) | 2024-09-10 |
| IL313857A (en) | 2024-08-01 |
| EP4452979A4 (en) | 2025-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
| EP4647121A3 (en) | Novel uses of piperidinyl-indole derivatives | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| TW200611702A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| TW200736213A (en) | Dicarboxylic acid derivatives and their use | |
| MX2024007911A (es) | Compuestos. | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| WO2009132656A3 (en) | Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin | |
| MX2010006033A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso. | |
| MX2025015490A (es) | Compuestos | |
| TW200621765A (en) | Substituted phenylaminothiazoles and their use | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
| GB2557471A (en) | Arginine silicate inositol for improving cognitive function | |
| WO2024054688A3 (en) | Therapeutic combinations for movement disorders | |
| WO2018154118A3 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| MX2024014447A (es) | Compuestos | |
| TW200724532A (en) | Pyrimidinecarboxylic acid derivatives and their use | |
| WO2004042389A3 (en) | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) | |
| WO2006023452A3 (en) | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases | |
| MX2025015493A (es) | Compuestos | |
| WO2006089664A3 (de) | Heterocyclylamid-substituierte imidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240705 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251222 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251222 |